Major Review: Only 3 Supplements Show Promise for Depression, But Evidence Remains Weak

Anyone who has lingered in the supplement aisle, scanning labels for something that might ease a low mood, has faced the same question: does any of this actually work? The shelves promise relief through fish oil, vitamin D, saffron, and dozens of other plant-based or nutrient-derived compounds, often marketed as gentler and cheaper alternatives to prescription antidepressants. A sweeping new analysis of the evidence suggests the answer is far more uncertain than the marketing suggests.

Researchers conducted a network meta-analysis of 163 randomized controlled trials involving 15,757 adults with major depressive disorder. The scope was ambitious: they examined 137 different nutraceutical or plant-based treatments, comparing them either to placebo or to standard antidepressant medications, then tracking changes in depressive symptoms, treatment response, and dropout rates. But the researchers did something that sets this work apart—they actively searched for reasons the results might mislead. What they found was troubling.

Across the studies, many treatments appeared to outperform placebo, sometimes dramatically. But when the researchers filtered out trials with higher risk of bias, statistical outliers, and other methodological problems, the field narrowed sharply. Only a handful of compounds continued to show any signal of benefit. Eicosapentaenoic acid, an omega-3 fatty acid commonly called EPA, emerged as the most promising candidate, supported by twenty trials involving 8,483 people—making it the most thoroughly studied compound in the review. Vitamin D3 and a specific St. John's wort extract labeled ZE117 also appeared to reduce depressive symptoms compared with placebo. But here the numbers shrink considerably: vitamin D3 rested on just three trials with 344 participants, while ZE117 came from three trials with 207 people. Those are small foundations on which to build confidence.

The researchers uncovered a pattern that raised deeper concerns. The larger the reported benefit of a supplement, the lower the quality of the study tended to be. When they examined the effect sizes for EPA, vitamin D3, and ZE117 in their more rigorous analysis, the results were larger than would typically be expected from a high-quality, double-blind, placebo-controlled depression trial. The researchers described these effects as unrealistically large—not necessarily proof that the treatments don't work, but a red flag that the study designs themselves may have inflated the apparent benefits. Trust in the existing results, they concluded, should be cautious.

Other compounds showed intriguing signals. Different St. John's wort extracts were associated with higher remission rates than placebo. Saffron demonstrated larger effects, and curcumin showed medium-sized reductions in anxiety symptoms linked to depression. Yet these findings too rested on relatively small numbers of trials, and the researchers emphasized that more evidence would be needed before drawing firm conclusions. They did note that plausible biological mechanisms exist—saffron, for instance, may enhance brain-derived neurotrophic factor expression and synaptic plasticity, both often impaired in depression.

The safety picture remains incomplete. The researchers found no supplement class significantly less tolerable than placebo, though citicoline was associated with more people dropping out of trials. But many original studies failed to provide adequate safety data, particularly regarding long-term effects or the risk of suicidality—gaps that matter when people are considering these compounds as alternatives to established treatments.

The researchers' conclusion is measured but clear: only a few nutraceuticals and phytoceuticals show enough promise to justify further, more rigorous investigation. EPA, vitamin D3, and certain St. John's wort extracts qualify as candidates for that next phase of research. The operative word is potential. With overall confidence in the evidence rated low to very low, there remains a substantial distance between "this might work" and "we know this works." Anyone standing in that supplement aisle, hoping for relief, deserves research that closes that gap.